Allspring Global Investments Holdings LLC lessened its stake in shares of Geron Co. (NASDAQ:GERN – Free Report) by 6.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 284,659 shares of the biopharmaceutical company’s stock after selling 18,849 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.06% of Geron worth $914,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Cerity Partners LLC acquired a new stake in shares of Geron in the 4th quarter worth about $26,000. CIBC Asset Management Inc acquired a new stake in shares of Geron in the 4th quarter worth about $27,000. Nisa Investment Advisors LLC raised its holdings in shares of Geron by 117.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 11,420 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 6,180 shares during the last quarter. American Trust acquired a new stake in shares of Geron in the 1st quarter worth about $27,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Geron in the 4th quarter worth about $45,000. Institutional investors own 65.44% of the company’s stock.
Geron Trading Down 3.1 %
Shares of GERN stock opened at $1.85 on Thursday. The company has a 50 day moving average of $2.04 and a 200-day moving average of $2.66. The company has a quick ratio of 3.75, a current ratio of 3.75 and a debt-to-equity ratio of 0.10. Geron Co. has a 12-month low of $1.73 and a 12-month high of $3.84. The firm has a market cap of $1.00 billion, a P/E ratio of -5.14 and a beta of 0.82.
Wall Street Analyst Weigh In
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
- Five stocks we like better than Geron
- The Role Economic Reports Play in a Successful Investment Strategy
- Investing in large cap stocks: Diving into big caps
- Stock Sentiment Analysis: How it Works
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- 3 Tickers Leading a Meme Stock Revival
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.